Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Mucolipidoses (MLs) II and III are rare lysosomal diseases caused by deficiency of GlcNAc-1-phosphotransferase, and clinical manifestations are multisystemic. Clinical and demographic data from 1983 to 2013 were obtained retrospectively. Twenty-seven patients were included (ML II = 15, ML III α/beta = 9, ML III gamma = 3). The median age at diagnosis was 2.7 years. The predominant clinical presentations were skeletal symptoms. The ML II patients showed physical and cognitive impairment, while the ML III α/beta patients have more somatic abnormalities and usually were delayed in early development as compared with ML III gamma patients. This is the most comprehensive study exploring characteristics of Brazilian patients with MLs II and III.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824887PMC
http://dx.doi.org/10.1055/s-0039-1697605DOI Listing

Publication Analysis

Top Keywords

mls iii
8
iii
7
patients
5
clinical
4
clinical characterization
4
characterization mucolipidoses
4
mucolipidoses iii
4
iii multicenter
4
multicenter study
4
study mucolipidoses
4

Similar Publications

Unlabelled: Objective: To assess the deformation of the bladder-neck opening and the impact of the bladder-neck angle (BNA) on urination in male patients by fluid-structure interaction (FSI) analysis.

Methods: We established geometric models of the bladder, prostate and urethra were established, incorporating both normal and enlarged BNAs, and assessed the effects of BNA alteration on urinary flow by FSI simulation of the flow rate and pressure of the urine within the bladder, bladder neck and urethra, and that of prostate displacement as well. We retrospectively analyzed the clinical data on 145 male patients from the Second Hospital of Hebei Medical University between June 2020 and June 2023, 39 with acute urine retention (the AUR group) and 106 without (the non-AUR group), and evaluate the impact of BNA on urination based on the urinary flow rate and prostate volume.

View Article and Find Full Text PDF

Optilume® for Urethral Strictures: A Comprehensive Review.

Cureus

April 2025

Urology, Unidade Local de Saúde de Amadora/Sintra (ULS Amadora/Sintra), Lisbon, PRT.

Urethral stricture disease treatment presents significant challenges due to high recurrence rates and limited minimally invasive options. This review evaluates the efficacy, safety, and clinical applicability of the Optilume® drug-coated balloon, which combines mechanical urethral dilation with paclitaxel delivery, as an innovative alternative to traditional treatments.  A narrative review was conducted using PubMed, focusing on studies published in the last decade addressing the use of Optilume® for urethral strictures.

View Article and Find Full Text PDF

Emerging threats: Listeria monocytogenes with acquired multidrug resistance from food in China, 2012-2022.

Int J Food Microbiol

August 2025

Key Laboratory of Food Safety Risk Assessment, National Health Commission of the People's Republic of China, China National Center for Food Safety Risk Assessment, Beijing, China; Department of Nutrition and Food Hygiene, School of Population Medicine and Public Health, Chinese Academy of Medical Sc

Listeria monocytogenes is a foodborne pathogen that poses threat to food safety and public health. Generally, the rates of resistance to clinically important antibiotics in L. monocytogenes are low.

View Article and Find Full Text PDF

Brainstem neural conduction was investigated in 78 very low birthweight (VLBW) at 36 weeks of postconceptional age while diagnosing neonatal bronchopulmonary dysplasia (BPD). The maximum length sequence technique was used to study brainstem auditory evoked response (MLS BAER). Compared with healthy controls, VLBW babies diagnosed with BPD manifested significant prolongation of wave V latency and I-V, I-III and III-V intervals at all 91-910/s clicks.

View Article and Find Full Text PDF

The goal of this study is to report the updated 3-year safety and efficacy outcomes of the intervention arm of the ROBUST III randomized controlled trial, comparing the Optilume® drug-coated balloon (DCB) with standard endoscopic management of recurrent male anterior urethral stricture. Eligible patients included adult men with recurrent anterior urethral stricture ≤3 cm in length and ≤12 Fr in diameter, International Prostate Symptom Score (IPSS) ≥11, and peak flow rate (Qmax) <15 mL/s. Patients were randomized to treatment with the Optilume DCB or standard-of-care endoscopic management.

View Article and Find Full Text PDF